PharmaSTART™
SUPPORT FOR TRANSLATING AND ADVANCING RESEARCH AND TECHNOLOGY

PharmaSTART™ is a consortium of research organizations led by SRI International that offers translational drug development services to help California-based universities, research institutes, and small biotech companies bridge the gap between identifying exciting new drug discoveries and bringing them successfully through clinical development. The goal of PharmaSTART is to facilitate the translation and funding of discovery research from California based Universities and their small cap companies, by offering drug development consulting, networking, and drug development services including lead development, GLP toxicology, analytical and regulatory services and cGMP manufacturing.

Key Objectives:

• to facilitate development and translation of drug from within Universities and Medical Centers into industry
• to provide a comprehensive and specific drug development plan that provides a road map for drug development to University faculty or faculty associated spin off companies
• to support and foster inter-institutional collaborations in research, development and clinical testing
• to educate consortium members in the process of drug development
• to foster and connect pharmaceutical and venture capital investment to emerging drug candidates
• to enhance collaborations and competitiveness for development-directed government grant support
• to facilitate the development of new drugs that address orphan diseases
• to spearhead new inter-institutional initiatives for support of drug development infrastructure and drug development